Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Neurology2024Vol. 23(4), pp. 393–403
Citations Over TimeTop 1% of 2024 papers
Eugenio Mercuri, Juan J. Vílchez, Odile Boespflug‐Tanguy, Craig M. Zaidman, Jean K. Mah, Nathalie Goemans, Wolfgang Müller‐Felber, E. Niks, Ulrike Schara‐Schmidt, Enrico Bertini, Giacomo P. Comi, Katherine D. Mathews, Laurent Servais, Krista Vandenborne, Jessika Johannsen, Sonia Messina, Stefan Spinty, Laura McAdam, Kathryn Selby, Barry J. Byrne, Chamindra G. Laverty, Kevin Carroll, Giulia Zardi, Sara Cazzaniga, N. Coceani, P. Bettica, Craig M. McDonald, Gyula Acsádi, Giovanni Baranello, Astrid Blaschek, John F. Brandsema, Claudia Brogna, Claudio Bruno, Anne M. Connolly, Imelda J. M. de Groot, Liesbeth De Waele, Erika Finanger, Richard S. Finkel, Teresa Gidaro, M. Guglieri, Amy Harper, Mercedes López Lobato, Marcos Madruga Garrido, Francesca Magri, Georgios Manousakis, Riccardo Masson, Migvis Monduy, Nuria Muelas Gómez, Francina Munell, A. Nascimento, Yoram Nevo, Yann Péréon, H. Phan, Valeria Sansone, Mariacristina Scoto, Dragana Vučinić, Tracey Willis
Related Papers
- → miR‐31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy(2011)153 cited
- → The Frequency of Revertants in mdx Mouse Genetic Models for Duchenne Muscular Dystrophy(1992)140 cited
- → Milder course in Duchenne patients with nonsense mutations and no muscle dystrophin(2014)35 cited
- → Influence of full-length dystrophin on brain volumes in mouse models of Duchenne muscular dystrophy(2018)12 cited